US-based medical technology company Masimo has obtained the CE mark for its O3 regional oximetry with the O3 pediatric sensor.
Regional oximetry, also known as issue or cerebral oximetry, assists clinicians in monitoring cerebral oxygenation and detecting regional hypoxemia.
The mechanism of the O3 regional oximetry uses near-infrared spectroscopy (NIRS) and reflectance pulse oximetry for a continuous monitor of absolute and trended regional tissue oxygen saturation (rSO2) in the cerebral region.
It results in an early detection, fixing the unproportionate delivery of oxygen to the brain and vital organs thereby helping patients avoid postoperative morbidity and adverse outcomes.
The introduction of the O3 pediatric sensor expands the availability of the O3 regional oximetry monitoring of rSO2 for pediatric patients weighing less than 40kg (88lbs).
Masimo founder and CEO Joe Kiani said: “O3 regional oximetry provides access to valuable data about cerebral oxygen saturation, and studies have shown that the risks of cerebral desaturations include neurological injury, increased length of hospital stays, increased time on mechanical ventilation, and other adverse outcomes.
“With adult trend accuracy of 3% and absolute accuracy of 4% without controlling CO2, and trend accuracy of 3% in pediatric patients, Masimo O3 should help clinicians build a better picture of brain oxygenation and hopefully better outcomes for all of their patients, including pediatric ones.”
Masimo’s O3 regional oximetry and SedLine brain function monitoring operate on a single platform, Masimo Root.
Image: Masimo Root with SedLine and O3 with Pediatric Sensor. Photo: courtesy of Masimo.